Therapeutic Modalities | Industry Spotlights & Insight Articles

Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma

Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.

We had the privilege of sitting down with Angelica Loskog, Professor of Immunotherapy at Uppsala University in Sweden and the CEO of Lokon Pharma, a cutting-edge immunotherapy company making strides in the field. As a leader in the realm of oncolytic viruses and immunostimulatory gene therapy, Professor Loskog shared valuable insights into Lokon Pharma's groundbreaking work.